Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

New Adjuvant Treatment Strategies for Early-Stage HER2-Positive Breast Cancer: Clinical and Shared Decision Making Implications for the Oncology Nurse
Slideset - These downloadable slides, from our live meeting series on adjuvant therapy for HER2+ EBC, review the current clinical rational and most recent data on dual HER2-targeted adjuvant therapy with trastuzumab and pertuzumab as well as the use of extended therapy with neratinib for patients at high risk of disease recurrence. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - April 19, 2018 Category: Cancer & Oncology Source Type: research

At-A-Glance: Nursing Considerations for Adjuvant Treatment Approaches for Patients With HER2+ Early Breast Cancer
PDF - Download this pocket guide for a summary of the optimal use of dual HER2-targeted adjuvant therapy with trastuzumab and pertuzumab as well as the use of extended therapy with neratinib for patients with HER2+ EBC at high risk of disease recurrence. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - April 18, 2018 Category: Cancer & Oncology Source Type: research

Understanding Evolving Adjuvant Treatment Approaches for HER2-Positive Breast Cancer
Discussion - Adjuvant treatment for HER2+ EBC is evolving with new agents and potentially practice-changing clinical trial data. Read my thoughts on how I am using these new findings in my clinical practice. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - April 12, 2018 Category: Cancer & Oncology Source Type: research

Biosimilars in the Evolving Cancer Care Landscape: Experts Address Current Questions, Controversies, and Impact on Clinical Practice
Slideset - Download these slides from a live symposium to examine the impact of biosimilar drugs on the care of patients with cancer and discuss current questions regarding the use of these agents in clinical practice. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - March 8, 2018 Category: Cancer & Oncology Source Type: research

My Take: Integrating Biosimilars Into an Oncology Practice
Discussion - Multiple biosimilars are now approved for the treatment of active cancers. Here ’s what oncologists need to know. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - January 18, 2018 Category: Cancer & Oncology Source Type: research

Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients
Slideset - Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 14, 2017 Category: Cancer & Oncology Source Type: research

SELECT-D: Dalteparin vs Rivaroxaban Anticoagulation Therapy for Patients With Cancer at Risk of VTE Recurrence
Slideset - Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - December 13, 2017 Category: Cancer & Oncology Source Type: research

Expert Perspectives on Biosimilar Agents
Slideset - In these downloadable slides, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - November 16, 2017 Category: Cancer & Oncology Source Type: research

Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice
Slideset - In this downloadable slideset, Sara Hurvitz, MD, FACP, discusses the latest clinical data for optimal treatment of metastatic TNBC, and highlights promising agents under investigation. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - November 14, 2017 Category: Cancer & Oncology Source Type: research

Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice
Learning Module - Sara Hurvitz, MD, FACP, provides her expert perspective on leveraging the latest clinical trial results for customized treatment of metastatic TNBC based on patient and disease characteristics. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - November 14, 2017 Category: Cancer & Oncology Source Type: research

Highlights From the 2017 ESMO Congress
Learning Module - In this text module and accompanying downloadable slideset, experts review key study results presented at the 2017 ESMO annual meeting across multiple malignancies including advanced NSCLC, breast cancer, bladder cancer, renal cell carcinoma, gastric/gastroesophageal cancer, HNSCC, and hepatocellular carcinoma. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - October 31, 2017 Category: Cancer & Oncology Source Type: research

European Society of Medical Oncology 2017 Congress
Slideset - In this downloadable slideset, Richard Finn, MD; Leora Horn, MD, MSc, FRCPC; Yelena Y. Janjigian, MD; Joyce O ’Shaughnessy, MD; Elizabeth R. Plimack, MD, MS and Tanguy Seiwert, MD, review important clinical presentations across multiple cancers from the 2017 oncology meeting in Madrid. (Source: Clinical Care Options Breast Cancer)
Source: Clinical Care Options Breast Cancer - September 27, 2017 Category: Cancer & Oncology Source Type: research